Print
Email
Print Edition StoriesTuesday, November 17, 2009
Clinical Data names scientific board
By Mass High Tech staff
MHT's Galen Moore: Honoring innovation in New England
Funding drugs for rare diseases
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Clinical Data Inc. has formed a scientific advisory board for its PGxHealth division, which develops the Familion line of genetic tests.
Among the cardiovascular genetics experts on the board are Michael Ackerman, pediatric cardiologist at the Mayo Clinic, director of Mayo’s Long QT Syndrome Clinic and director of the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory; Martin Maron, director of the Hypertrophic Cardiomyopathy Center at Tufts Medical Center; Silvia Priori, professor of medicine and director of cardiovascular genetics at Langone Medical Center, New York University, as well as associate professor of cardiology and director of molecular cardiology at Fondazione Maugeri University of Pavia, Italy; Jeffrey Towbin, director of cardiology and co-director of Heart Institute at Cincinnati Children’s Hospital; and Arthur Wilde, of Academic Medical Center in Amsterdam.
Clinical Data (Nasdaq: CLDA) is developing early and late stage targeted therapeutics and genetic and pharmacogenomic tests that detect diseases and help predict drug safety, tolerability and efficacy.
The company has stressed its intention to focus on late-stage drug development. Earlier this month, it sold some of its assets — those associated with its Avalon Pharmaceuticals acquisition — in a $1.5 million cash deal to Intrexon Corp.
Earlier this year, Clinical Data shed other assets, selling its Cogenics division to Caifornia-based Beckman Coulter Inc. for about $17 million.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.